Effects of Pennogenin 3-O-<i>β</i>-Chacotrioside, a Steroidal Saponin from <i>Rhizoma paridis</i>, on Proliferation Inhibition and Apoptosis Induction in Non-Small Cell Lung Cancer Cells
Jiang-hai Wu,Jia Liu,Dan Wang,Ting Liu,Shangyong Zheng,Hongliang Li
DOI: https://doi.org/10.1166/jbmb.2022.2208
2022-01-01
Journal of Biobased Materials and Bioenergy
Abstract:Rhizoma paridis is a traditional Chinese medicine that has been reported to have anti-cancer activity. However, the antitumor effect of pennogenin 3-O- β -chacotrioside (Formular: C 45 H 72 O 17 ), a steroidal saponin isolated from its extract, in lung cancer have not been well studied, its potential mechanisms remain unclear. In this paper, its effect on the cell viability of non-small cell lung cancer (NSCLC) was examined using the Cell Counting Kit-8 assay, the potential target proteins were screened by antibody microarrays, the potential pharmacological mechanisms were predicted using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein–protein interaction (PPI) analyses. Moreover, to further validate the findings, cell apoptosis and cell cycle arrest were measured by flow cytometry, cell invasion and migration were measured by Transwell assays, and apoptosis-related protein expression levels were measured using western blotting. The results showed that, after treatment by pennogenin 3-O- β -chacotrioside, the cell viability was significantly reduced. In addition, thirteen target proteins related to apoptosis and platinum drug resistance were screened out, and their PPIs were constructed. Moreover, it was confirmed to have effects in inducing apoptosis and promoting cell cycle arrest in NSCLC cells. The expression levels of apoptosis-related proteins, such as caspase 8, caspase 9, phospho-ERK1/2, phospho-p38, phospho-Akt, were decreased following the treatment, whereas the expression levels of cleaved caspase 3 and cytochrome C were increased. The findings of the present study highlight the potential of pennogenin 3-O- β -chacotrioside as a novel therapeutic agent.